P3 Health Partners Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share (Tables)

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2023

Schedule of Computation of Basic and Diluted Net Loss Per Share

The following table provides the computation of basic and diluted net loss per share:


	Three Months Ended March 31,
	2023		2022
	(in thousands, except per share data)
Net loss attributable to Class A common stockholders–basic and diluted	$	(9,199)	$	(10,577)
Weighted average Class A common shares outstanding–basic and diluted	41,579		41,579
Net loss per share attributable to Class A common stockholders–basic and diluted	$	(0.22)	$	(0.25)

Schedule of Potentially Dilutive Securities Excluded from the Computation of Diluted Net Loss Per Share

The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive.


	Three Months Ended March 31,
	2023	2022
	(in thousands)
Stock warrants (1)	11,248	10,819
Stock options (1)	5,487	2,134
Shares of Class V common stock (2)	201,972	202,025
Total	218,707	214,978

____________________

(1) Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share.

(2) Shares of Class V common stock at the end of the period, including shares tied to unvested Common Units, are considered potentially dilutive shares of Class A common stock under the application of the if-converted method.